Protagonist Therapeutics (NASDAQ:PTGX) Given New $106.00 Price Target at JPMorgan Chase & Co.

Protagonist Therapeutics (NASDAQ:PTGX) had its price target hoisted by stock analysts at JPMorgan Chase & Co. from $95.00 to $106.00 in a report released on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target indicates a potential upside of 4.08% from the company’s previous close.

PTGX has been the topic of several other research reports. Truist Financial boosted their price target on Protagonist Therapeutics from $88.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, January 5th. The Goldman Sachs Group lifted their price target on shares of Protagonist Therapeutics from $65.00 to $95.00 and gave the company a “neutral” rating in a report on Tuesday, March 3rd. Barclays raised their price objective on shares of Protagonist Therapeutics from $113.00 to $119.00 and gave the stock an “overweight” rating in a report on Thursday. Citizens Jmp increased their price target on Protagonist Therapeutics from $102.00 to $112.00 and gave the stock a “market outperform” rating in a research report on Thursday, February 26th. Finally, TD Cowen lifted their price objective on Protagonist Therapeutics from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $104.46.

Protagonist Therapeutics Price Performance

Shares of NASDAQ PTGX traded up $4.75 during mid-day trading on Thursday, hitting $101.84. The company had a trading volume of 1,326,762 shares, compared to its average volume of 775,111. Protagonist Therapeutics has a 12 month low of $39.60 and a 12 month high of $105.69. The firm has a market cap of $6.50 billion, a P/E ratio of -49.68 and a beta of 2.23. The business’s 50-day simple moving average is $86.37 and its 200-day simple moving average is $80.45.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.16). The firm had revenue of $7.44 million during the quarter, compared to analyst estimates of $14.92 million. Protagonist Therapeutics had a negative net margin of 282.83% and a negative return on equity of 19.89%. As a group, sell-side analysts predict that Protagonist Therapeutics will post 2.43 EPS for the current year.

Insider Activity

In other news, Director Lewis T. Williams sold 18,000 shares of the business’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $82.42, for a total transaction of $1,483,560.00. Following the completion of the sale, the director owned 7,825 shares in the company, valued at $644,936.50. The trade was a 69.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director William D. Waddill sold 20,000 shares of the company’s stock in a transaction on Friday, February 6th. The shares were sold at an average price of $83.68, for a total value of $1,673,600.00. Following the transaction, the director directly owned 7,825 shares in the company, valued at $654,796. This trade represents a 71.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 203,167 shares of company stock worth $16,889,199. 4.90% of the stock is owned by company insiders.

Institutional Trading of Protagonist Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Farther Finance Advisors LLC boosted its stake in shares of Protagonist Therapeutics by 110.6% in the 4th quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock valued at $26,000 after purchasing an additional 156 shares during the last quarter. Greenline Wealth Management LLC acquired a new position in Protagonist Therapeutics in the fourth quarter valued at approximately $27,000. Salomon & Ludwin LLC acquired a new position in Protagonist Therapeutics in the third quarter valued at approximately $29,000. EverSource Wealth Advisors LLC boosted its stake in Protagonist Therapeutics by 138.9% in the third quarter. EverSource Wealth Advisors LLC now owns 540 shares of the company’s stock valued at $36,000 after acquiring an additional 314 shares during the last quarter. Finally, Abich Financial Wealth Management LLC acquired a new stake in Protagonist Therapeutics during the 3rd quarter worth $62,000. 98.63% of the stock is owned by institutional investors.

Trending Headlines about Protagonist Therapeutics

Here are the key news stories impacting Protagonist Therapeutics this week:

• Positive Sentiment: FDA approval and partner milestone/royalty economics — J&J received U.S. FDA approval for ICOTYDE (icotrokinra), the first oral IL‑23R targeted peptide for moderate‑to‑severe plaque psoriasis. Approval triggered a $50M milestone payment to Protagonist and makes the company eligible for 6–10% royalties plus up to $580M in additional milestones, creating clear near‑ and longer‑term revenue streams. Access Newswire: Protagonist Announces FDA Approval of ICOTYDE
• Positive Sentiment: Analysts raising targets and ratings — Citigroup raised its PT to $125 (buy) and Barclays raised its PT to $119 (overweight), both implying double‑digit upside from current levels. Those upgrades reflect expectations for meaningful value capture from the J&J commercialization and support bullish investor sentiment. Benzinga: Analyst Coverage
• Positive Sentiment: Market/press framing the approval as strategic value creation — Coverage from MSN, BioSpace and Seeking Alpha highlights that ICOTYDE’s oral IL‑23R mechanism and complete‑clearance data could disrupt incumbents and add strategic value to Protagonist as a partner/royalty beneficiary. This narrative is driving investor interest. MSN: Wall Street on J&J Approval
• Neutral Sentiment: Informational conference materials and transcripts — Seeking Alpha posted the approval call transcript and slideshow, which provide detail on trial data, safety profile, and commercialization assumptions but don’t change the core economics already announced. Useful for modeling but not an additional catalyst by itself. Seeking Alpha: Approval Call Transcript
• Neutral Sentiment: Execution and timing risks remain — Revenue upside depends on J&J’s launch execution, uptake vs. large biologics, and the pace of royalty-bearing sales; most future payouts are contingent milestones. Also remember Protagonist previously reported a quarterly EPS miss, so profitability hinges on these partnership revenues scaling.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.